医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sengenics, a Leading Precision Medicine Focused Company, to Present at the Annual BIO CEO and Investor Conference

2020年01月28日 PM11:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Sengenics, a leading precision medicine focused company, today announced that Dr Arif Anwar, CEO of Sengenics, will present a company overview at the 2020 BIO CEO and Investor Conference. The presentation will take place at 3:15 PM EST on Monday, February 10, 2020 in the Wilder room at the New York Marriott Marquis.

Dr Arif Anwar will present an overview of the commercialisation strategy of the company and applications of its patented KREXTM technology for autoimmune and cancer immunotherapy drug response and ADR prediction.

Sengenics is currently co-developing complementary and companion diagnostic tests for several autoimmune and cancer immunotherapy drugs through partnerships with top pharmaceutical companies. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2020 and 2021.

Sengenics’ management team will also hold meetings with institutional investors and analysts from February 10 – 14 in New York. Accredited investors are invited to request a meeting during the conference through BIO’s One-on-One PartneringTM System.

About Sengenics

Sengenics is a precision medicine company that leverages its patented KREXTM technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREXTM can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005345/en/

CONTACT

Media

Farah Elena

Marketing Manager

Sengenics Corporation Pte Ltd

f.elena@sengenics.com

Business Development and Partnerships

Andrew James Jackson

Global Business Unit Director – Pharma

Sengenics Corporation Pte Ltd

a.jackson@sengenics.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作